319 related articles for article (PubMed ID: 29618351)
1. Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis.
Newcomer JW; Ng-Mak D; Rajagopalan K; Loebel A
BMC Health Serv Res; 2018 Apr; 18(1):243. PubMed ID: 29618351
[TBL] [Abstract][Full Text] [Related]
2. Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment.
Broder MS; Greene M; Yan T; Chang E; Hartry A; Yermilov I
Clin Ther; 2019 Feb; 41(2):221-232. PubMed ID: 30616973
[TBL] [Abstract][Full Text] [Related]
3. Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
Yan T; Greene M; Chang E; Houle CR; Waters HC; Tarbox MH; Broder MS
Clin Ther; 2020 Jan; 42(1):77-93. PubMed ID: 31928831
[TBL] [Abstract][Full Text] [Related]
4. Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics.
Ng-Mak D; Messali A; Huang A; Wang L; Loebel A
Am J Manag Care; 2019 Jul; 25(14 Suppl):S279-S286. PubMed ID: 31365818
[TBL] [Abstract][Full Text] [Related]
5. Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis.
Rajagopalan K; Wade S; Meyer N; Loebel A
Curr Med Res Opin; 2017 May; 33(5):813-820. PubMed ID: 28098496
[TBL] [Abstract][Full Text] [Related]
6. Hospitalization risk among adults with bipolar I disorder treated with lurasidone versus other oral atypical antipsychotics: a retrospective analysis of Medicaid claims data.
Niu X; Veeranki P; Dennen S; Dembek C; Laubmeier K; Liu Y; Williams GR; Loebel A
Curr Med Res Opin; 2021 May; 37(5):839-846. PubMed ID: 33682547
[TBL] [Abstract][Full Text] [Related]
7. Hospitalization risk in pediatric patients with bipolar disorder treated with lurasidone vs. other oral atypical antipsychotics: a real-world retrospective claims database study.
Kadakia A; Dembek C; Liu Y; Dieyi C; Williams GR
J Med Econ; 2021; 24(1):1212-1220. PubMed ID: 34647502
[TBL] [Abstract][Full Text] [Related]
8. Hospitalization risk in bipolar disorder patients treated with lurasidone versus other atypical antipsychotics.
Ng-Mak D; Halpern R; Rajagopalan K; Loebel A
Curr Med Res Opin; 2019 Feb; 35(2):211-219. PubMed ID: 29625538
[TBL] [Abstract][Full Text] [Related]
9. Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release.
Rajagopalan K; O'Day K; Meyer K; Pikalov A; Loebel A
J Med Econ; 2013 Aug; 16(8):987-96. PubMed ID: 23742620
[TBL] [Abstract][Full Text] [Related]
10. Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR.
Restelli U; García-Goñi M; Lew-Starowicz M; Mierzejewski P; Silvola S; Mayoral-van Son J; Croce D; Rocca P; Crespo-Facorro B
Clin Drug Investig; 2020 Sep; 40(9):861-871. PubMed ID: 32648201
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of lurasidone vs quetiapine extended-release (XR) in patients with bipolar depression.
Rajagopalan K; Meyer K; O'Day K; Denno M; Loebel A
J Med Econ; 2015; 18(10):821-7. PubMed ID: 25985265
[TBL] [Abstract][Full Text] [Related]
12. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.
Meyer JM; Mao Y; Pikalov A; Cucchiaro J; Loebel A
Int Clin Psychopharmacol; 2015 Nov; 30(6):342-50. PubMed ID: 26196189
[TBL] [Abstract][Full Text] [Related]
13. Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population.
Yu AP; Atanasov P; Ben-Hamadi R; Birnbaum H; Stensland MD; Philips G
Value Health; 2009; 12(5):708-15. PubMed ID: 19508658
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Lurasidone Versus Quetiapine for the Treatment of Delirium in Critically Ill Patients.
Fox MA; Elefritz JL; Huang BM; Hunley C
J Intensive Care Med; 2020 Apr; 35(4):394-399. PubMed ID: 29357776
[TBL] [Abstract][Full Text] [Related]
15. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
Seetasith A; Greene M; Hartry A; Burudpakdee C
J Med Econ; 2018 Sep; 21(9):888-901. PubMed ID: 29862860
[TBL] [Abstract][Full Text] [Related]
16. Patient Characteristics Associated With Use of Lurasidone Versus Other Atypical Antipsychotics in Patients With Bipolar Disorder: Analysis From a Claims Database in the United States.
Tohen M; Ng-Mak D; Rajagopalan K; Halpern R; Chuang CC; Loebel A
Prim Care Companion CNS Disord; 2017 Jun; 19(3):. PubMed ID: 28590601
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study.
Loebel A; Cucchiaro J; Xu J; Sarma K; Pikalov A; Kane JM
Schizophr Res; 2013 Jun; 147(1):95-102. PubMed ID: 23583011
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
Rajagopalan K; Hassan M; O'Day K; Meyer K; Grossman F
J Med Econ; 2013 Jul; 16(7):951-61. PubMed ID: 23701260
[TBL] [Abstract][Full Text] [Related]
19. Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia.
Awad G; Ng-Mak D; Rajagopalan K; Hsu J; Pikalov A; Loebel A
BMC Psychiatry; 2016 Jun; 16():176. PubMed ID: 27245981
[TBL] [Abstract][Full Text] [Related]
20. Hospitalization Risk for Adults with Bipolar I Disorder Treated with Oral Atypical Antipsychotics as Adjunctive Therapy with Mood Stabilizers: A Retrospective Analysis of Medicaid Claims Data.
Niu X; Dennen S; Dembek C; Laubmeier K; Liu Y; Veeranki P; Tocco M; Williams GR
Curr Ther Res Clin Exp; 2021; 94():100629. PubMed ID: 34306269
[No Abstract] [Full Text] [Related]
[Next] [New Search]
